Cargando…

Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance

Intraperitoneal dissemination of ovarian cancers is preceded by the development of chemoresistant tumors with malignant ascites. Despite the high levels of chemoresistance and relapse observed in ovarian cancers, there are no in vitro models to understand the development of chemoresistance in situ....

Descripción completa

Detalles Bibliográficos
Autores principales: Ward Rashidi, Maria R., Mehta, Pooja, Bregenzer, Michael, Raghavan, Shreya, Fleck, Elyse M., Horst, Eric N., Harissa, Zainab, Ravikumar, Visweswaran, Brady, Samuel, Bild, Andrea, Rao, Arvind, Buckanovich, Ronald J., Mehta, Geeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624324/
https://www.ncbi.nlm.nih.gov/pubmed/31299607
http://dx.doi.org/10.1016/j.neo.2019.06.005
_version_ 1783434247801929728
author Ward Rashidi, Maria R.
Mehta, Pooja
Bregenzer, Michael
Raghavan, Shreya
Fleck, Elyse M.
Horst, Eric N.
Harissa, Zainab
Ravikumar, Visweswaran
Brady, Samuel
Bild, Andrea
Rao, Arvind
Buckanovich, Ronald J.
Mehta, Geeta
author_facet Ward Rashidi, Maria R.
Mehta, Pooja
Bregenzer, Michael
Raghavan, Shreya
Fleck, Elyse M.
Horst, Eric N.
Harissa, Zainab
Ravikumar, Visweswaran
Brady, Samuel
Bild, Andrea
Rao, Arvind
Buckanovich, Ronald J.
Mehta, Geeta
author_sort Ward Rashidi, Maria R.
collection PubMed
description Intraperitoneal dissemination of ovarian cancers is preceded by the development of chemoresistant tumors with malignant ascites. Despite the high levels of chemoresistance and relapse observed in ovarian cancers, there are no in vitro models to understand the development of chemoresistance in situ. Method: We describe a highly integrated approach to establish an in vitro model of chemoresistance and stemness in ovarian cancer, using the 3D hanging drop spheroid platform. The model was established by serially passaging non-adherent spheroids. At each passage, the effectiveness of the model was evaluated via measures of proliferation, response to treatment with cisplatin and a novel ALDH1A inhibitor. Concomitantly, the expression and tumor initiating capacity of cancer stem-like cells (CSCs) was analyzed. RNA-seq was used to establish gene signatures associated with the evolution of tumorigenicity, and chemoresistance. Lastly, a mathematical model was developed to predict the emergence of CSCs during serial passaging of ovarian cancer spheroids. Results: Our serial passage model demonstrated increased cellular proliferation, enriched CSCs, and emergence of a platinum resistant phenotype. In vivo tumor xenograft assays indicated that later passage spheroids were significantly more tumorigenic with higher CSCs, compared to early passage spheroids. RNA-seq revealed several gene signatures supporting the emergence of CSCs, chemoresistance, and malignant phenotypes, with links to poor clinical prognosis. Our mathematical model predicted the emergence of CSC populations within serially passaged spheroids, concurring with experimentally observed data. Conclusion: Our integrated approach illustrates the utility of the serial passage spheroid model for examining the emergence and development of chemoresistance in ovarian cancer in a controllable and reproducible format.
format Online
Article
Text
id pubmed-6624324
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-66243242019-07-23 Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance Ward Rashidi, Maria R. Mehta, Pooja Bregenzer, Michael Raghavan, Shreya Fleck, Elyse M. Horst, Eric N. Harissa, Zainab Ravikumar, Visweswaran Brady, Samuel Bild, Andrea Rao, Arvind Buckanovich, Ronald J. Mehta, Geeta Neoplasia Original article Intraperitoneal dissemination of ovarian cancers is preceded by the development of chemoresistant tumors with malignant ascites. Despite the high levels of chemoresistance and relapse observed in ovarian cancers, there are no in vitro models to understand the development of chemoresistance in situ. Method: We describe a highly integrated approach to establish an in vitro model of chemoresistance and stemness in ovarian cancer, using the 3D hanging drop spheroid platform. The model was established by serially passaging non-adherent spheroids. At each passage, the effectiveness of the model was evaluated via measures of proliferation, response to treatment with cisplatin and a novel ALDH1A inhibitor. Concomitantly, the expression and tumor initiating capacity of cancer stem-like cells (CSCs) was analyzed. RNA-seq was used to establish gene signatures associated with the evolution of tumorigenicity, and chemoresistance. Lastly, a mathematical model was developed to predict the emergence of CSCs during serial passaging of ovarian cancer spheroids. Results: Our serial passage model demonstrated increased cellular proliferation, enriched CSCs, and emergence of a platinum resistant phenotype. In vivo tumor xenograft assays indicated that later passage spheroids were significantly more tumorigenic with higher CSCs, compared to early passage spheroids. RNA-seq revealed several gene signatures supporting the emergence of CSCs, chemoresistance, and malignant phenotypes, with links to poor clinical prognosis. Our mathematical model predicted the emergence of CSC populations within serially passaged spheroids, concurring with experimentally observed data. Conclusion: Our integrated approach illustrates the utility of the serial passage spheroid model for examining the emergence and development of chemoresistance in ovarian cancer in a controllable and reproducible format. Neoplasia Press 2019-07-09 /pmc/articles/PMC6624324/ /pubmed/31299607 http://dx.doi.org/10.1016/j.neo.2019.06.005 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Ward Rashidi, Maria R.
Mehta, Pooja
Bregenzer, Michael
Raghavan, Shreya
Fleck, Elyse M.
Horst, Eric N.
Harissa, Zainab
Ravikumar, Visweswaran
Brady, Samuel
Bild, Andrea
Rao, Arvind
Buckanovich, Ronald J.
Mehta, Geeta
Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance
title Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance
title_full Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance
title_fullStr Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance
title_full_unstemmed Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance
title_short Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance
title_sort engineered 3d model of cancer stem cell enrichment and chemoresistance
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624324/
https://www.ncbi.nlm.nih.gov/pubmed/31299607
http://dx.doi.org/10.1016/j.neo.2019.06.005
work_keys_str_mv AT wardrashidimariar engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT mehtapooja engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT bregenzermichael engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT raghavanshreya engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT fleckelysem engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT horstericn engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT harissazainab engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT ravikumarvisweswaran engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT bradysamuel engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT bildandrea engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT raoarvind engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT buckanovichronaldj engineered3dmodelofcancerstemcellenrichmentandchemoresistance
AT mehtageeta engineered3dmodelofcancerstemcellenrichmentandchemoresistance